Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Michael Porter acquired 25,000 shares of the company’s stock on the open market in a transaction dated Tuesday, December 17th. The stock was purchased at an average cost of $4.75 per share, for a total transaction of $118,750.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock opened at $5.15 in last trading session, and closed at $5.16, trading in the range of $4.98 – $5.18. The stock showed a positive weekly performance of 4.88%.
Synthetic Biologics Inc (NYSEMKT:SYN) and Intrexon Corp. have announced that they have initiated development of novel biologic approaches for the prevention, as well as the acute and chronic treatment of a subset of irritable bowel syndrome pathologies specifically caused by auto- antibodies. Synthetic Biologics Inc (NYSEMKT:SYN) shares closed at $1.55 on last trade day, by decreasing -0.64%. Stock 52 week range is $0.95 – $2.10. Company’s market capitalization is $69.21 billion.
StemCells Inc (NASDAQ:STEM) Expanding Trial in Age-Related Eye Affliction. StemCells Inc (NASDAQ:STEM) stock opened at $1.30 in last trading session and closed at $1.28. The 52 week range of the stock is $1.16 – $2.13 and the day range was $1.23 – $1.33.
Achillion Pharmaceuticals (NASDAQ:ACHN) major shareholder Qvt Associates Gp Llc sold 121,205 shares of Achillion Pharmaceuticals stock in a transaction dated Thursday, December 26th. The shares were sold at an average price of $3.44, for a total transaction of $416,945.20. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock fell -0.29% and finished the last session at $3.38. The EPS of the stock remained -0.62. Company’s market capitalization is $326.65 billion.